etectRx, Inc., an early stage digital health company, said the US Patent and Trademark Office issued a patent for an “electronic medication compliance monitoring system and associated methods.”
It said the patent covers “an ingestible electronic tag system and a method for monitoring a patient’s compliance with a medication program.”
etectRx said it has exclusive rights to the patented technology.
etectRx said it is developing an ingestible event marker — the ID-Cap System — which gives clinicians the ability, in real time, to accurately monitor patients’ medication adherence on a per-dose basis.
“The ID-Cap System uses a novel ingestible sensor within a pharmaceutical capsule that is powered by stomach fluid and emits a very low-power digital message from within the patient each time an ID-Cap is ingested,” said etectRx.
“That message is sent to a wearable reader and can be further forwarded to the patient’s smartphone.
“The company is successfully employing the technology in IRB-approved clinical trials and working toward a 510k application for the ID-Cap System in 2018.”
etectRx CEO Harry Travis said: “This patent is an important component of etectRx’s intellectual property portfolio covering the ID-Cap system and components and our unique methods for monitoring patient compliance with a medication program.”